A Phase 1 Study of Acalabrutinib in Japanese Adult Patients with Advanced B-cell Malignancies

Trial Identifier: D8220C00001
Sponsor: AstraZeneca
Start Date: June 2017
Primary Completion Date: October 2022
Study Completion Date: December 2025

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
JP Chiba-shi, JP, 260-8717
JP Chuo-ku, JP, 104-0045
JP Fukuoka-shi, JP, 812-8582
JP Isehara-shi, JP, 259-1193
JP Izumo-shi, JP, 693-8501
JP Matsuyama-shi, JP, 791-0280
JP Nagoya-shi, JP, 460-0001
JP Nagoya-shi, JP, 464-8681
JP Niigata-shi, JP, 951-8520
JP Okayama-shi, JP, 700-8558
JP Sapporo-shi, JP, 060-8638
JP Sendai-shi, JP, 980-8574
JP Shimotsuke-shi, JP, 329-0498
JP Suita-shi, JP, 565-0871